Christopher Doe - Concepedia

Author

Christopher Doe

Also Known As

C. P. A. Doe, C. P. Doe, C.P.A Doe, C.P.A. Doe, CP Doe, Christopher Doe, Christopher P A Doe, Christopher P Doe, Christopher P. A. Doe, Christopher P. Doe

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)GlaxoSmithKline (United Kingdom)University of Leeds Research Triangle Park Foundation

About

Christopher Doe is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	727
2	Natural Sciences	3	3	181
3	Health Sciences	2	2	87
4	Public Health	1	1	18
5	Anesthesia	1	1	18

Christopher Doe

Publications

959

Citations

H-Index

Page 1

	Year	Citations
Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors Krista Goodman, Haifeng Cui, Sarah E. Dowdell, Journal of Medicinal Chemistry Indazole SubstitutionMedicinal ChemistryOral BioavailabilityRho KinaseMedicine	2006	154
Synthetic LXR agonists increase LDL in CETP species Pieter H.E. Groot, John Yates, Claire J. Stocker, Journal of Lipid Research	2005	116
Effects of p38 MAPK Inhibitor on Angiotensin II-Dependent Hypertension, Organ Damage, and Superoxide Anion Production Weike Bao, David J. Behm, Sandhya S. Nerurkar, Journal of Cardiovascular Pharmacology HypertensionCardiovascular PharmacologyP38 MapkPharmacotherapyAng Ii	2007	98
Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases Clark A. Sehon, Gren Z. Wang, Andrew Q. Viet, Journal of Medicinal Chemistry Medicinal ChemistryPotential Therapeutic AgentsBiochemistryRho KinaseMedicine	2008	72
Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity Robert A. Stavenger, Haifeng Cui, Sarah E. Dowdell, Journal of Medicinal Chemistry Drug TargetBioorganic ChemistryPharmacotherapyChemical BiologyPharmaceutical Chemistry	2006	71
Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice David J. Behm, Stephen Harrison, Zhaohui Ao, British Journal of Pharmacology HypertensionHeart FailureCardiovascular PharmacologyUrotensin‐ii Contractile ActivityCardiovascular Function	2003	65
A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetred beagle dogs Andrew J. Batey, Christopher Doe Journal of Pharmacological and Toxicological Methods Veterinary PhysiologyElectrophysiological EvaluationBeat-to-beat AnalysisKinesiologyQt/rr Interval Relationship	2002	47
Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction slowing from nonclinical models to clinical Bryony Heath, Yi Cui, S. Worton, Journal of Pharmacological and Toxicological Methods Ventricular ConductionMolecular PharmacologyCardiomyopathyCardiac MuscleCardiovascular Disease	2010	46
p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Thomas M. Behr, Marinela Berova, Christopher Doe, PubMed Heart FailureCardiovascular PharmacologyCell DeathP38 Mapk InhibitionP38 Mapk	2003	45
Urotensin-II: a novel systemic hypertensive factor in the cat Kristeen Maniscalco, Gerald P. Stankus, Alexandra Wibberley, Naunyn-Schmiedeberg s Archives of Pharmacology HypertensionUrologyAntihypertensive TherapyPhysiologyMedicine	2004	42

Page 1